Disease and symptom burden in systemic sclerosis: A patient perspective

Journal of Rheumatology

Volumn 34, Issue 8, 2007, Pages 1718-1726

  Suarez Almazor, Maria E ^a   Kallen, Michael A ^b   Roundtree, Aimee K ^a,c   Mayes, Maureen ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF HOUSTON DOWNTOWN   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Qualitative research; Quality of life; Systemic sclerosis

Indexed keywords

ADULT; ARTICLE; AWARENESS; CLINICAL ARTICLE; DEPRESSION; DISEASE ACTIVITY; DISEASE COURSE; EMOTIONAL STRESS; EXPECTATION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GROUNDED THEORY; HUMAN; INTERVIEW; MALAISE; MALE; PAIN; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITATIVE ANALYSIS; QUALITY OF LIFE; SELF ESTEEM; SOCIAL LIFE; SYMPTOM; SYSTEMIC SCLEROSIS; THEMATIC ANALYSIS; UNITED STATES;

ADULT; COST OF ILLNESS; DISEASE PROGRESSION; EMOTIONS; FEMALE; FOCUS GROUPS; HUMANS; INTERPERSONAL RELATIONS; INTERVIEWS AS TOPIC; LIFE STYLE; MALE; MARRIAGE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENTS; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC;

EID: 34547954776     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Kirwan J, Heiberg T, Hewlett S, et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol 2003;30:868-72.
2. Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
3. Khanna D, Furst DE, Clements PJ, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40.
4. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
5. Furst DE. Update on clinical trials in the rheumatic diseases. Curr Opin Rheumatol 1998;10:123-8.
6. Furst DE, Khanna D, Mattucci-Cerinic M, Silman AJ, Merkel PA, Foeldvari I. Scleroderma - developing measures of response. J Rheumatol 2005;32:2477-80.
7. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27-31.
8. Poole JL, Williams CA, Bloch DA, Hollak B, Spitz P. Concurrent validity of the Health Assessment Questionnaire Disability Index in Scleroderma. Arthritis Care Res 1995;8:189-93.
9. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
10. Zeller RA. Combining qualitative and quantitative techniques to develop culturally sensitive measures. In: Ostrow D, Kessler R, editors. Methodological issues in AIDS behavioral research. New York: Plenum Press; 1993:95-116.
11. Fern EF. The use of focus groups for idea generation: the effects of group size, acquaintanceship, and moderator on response quantity and quality. J Mark Res 1982;19:1-13.
12. Morgan DL. Designing focus group research. In: Stewart M, editor. Tools for primary care research. Thousand Oaks, CA: Sage Publishing; 1992:177-93.
13. Stewart DW, Shamdasani PN. Focus groups: Theory and practice. Thousand Oaks, CA: Sage Publishing; 1990.
14. Morgan DL. Focus groups. Annu Rev Sociol 1996;22:129-52.
15. Glaser BG, Strauss A. The discovery of grounded theory: Strategies for qualitative research. Chicago: Aldine; 1967.
16. Jeon YH. The application of grounded theory and symbolic interactionism. Scand J Caring Sci 2004;18:249-56.
17. Strauss A, Corbin J. Basics of qualitative research. Thousand Oaks, CA: Sage Publishing; 1998.
18. Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, et al. The impact of pain and symptoms of depression in scleroderma. Pain 2002;95:267-75.
19. Richards HL, Herrick AL, Griffin K, Gwilliam PD, Loukes J, Fortune DG. Systemic sclerosis: patients' perceptions of their condition. Arthritis Rheum 2003;49:689-96.
20. Richards H, Herrick AL, Griffin K, Gwilliam PD, Fortune DG. Psychological adjustment to systemic sclerosis -exploring the association of disease factors, functional ability, body related attitudes and fear of negative evaluation. Psychol Health Med 2004;9:29-39.
21. Sultan N, Pope JE, Clements PJ. The Health Assessment Questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology Oxford 2004;43:472-8.
22. Paquette DL, Falanga V. Cutaneous concerns of scleroderma patients. J Dermatol 2003;30:438-43.
23. Benrud-Larson LM, Heinberg LJ, Boling C, et al. Body image dissatisfaction among women with scleroderma: extent and relationship to psychosocial function. Health Psychol 2003;22:130-9.
24. Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592-600.
25. Legendre C, Allanore Y, Ferrand I, Kahan A. Evaluation of depression and anxiety in patients with systemic sclerosis. Joint Bone Spine 2005;72:408-11.
26. Matsuura E, Ohta A, Kanegae F, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003;30:1782-7.
27. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient-friendly Health Assessment Questionnaire format. Arthritis Rheum 1999;42:2220-30.
28. Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthritis Rheum 1996;39:1035-40.
29. Van Lankveld W, Teunissen H, Vonk M, Van den Hoogen F. Coping and cognitions as predictors of psychological distress in scleroderma. Ann Rheum Dis 2005;64 Suppl:900.
30. Trezza M, Krogh K, Egekvist H, Bjerring P, Laurberg S. Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol 1999;34:409-13.
31. Joachim G, Acorn S. Life with a rare chronic disease: the scleroderma experience. J Adv Nurs 2003;42:598-606.
32. Clements PJ. Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 1995;7:517-21.
33. Clements PJ, Wong WK, Hurwitz EL, et al. Correlates of the Disability Index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999;42:2372-80.
34. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
35. Clements PJ, Wong WK, Hurwitz EL, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001;44:653-61.
36. Georges C, Chassany O, Mouthon L, et al. Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 2005;24:3-10.
37. Johnson SR, Gladman DD, Schentag CT, Lee P. Quality of life in scleroderma: Compared to psoriatic arthritis, SLE, rheumatoid arthritis and healthy controls. J Rheumatol 2004;31:1425.
38. Ostojic PS, Damjanov NS. The Scleroderma Assessment Questionnaire (SAQ); A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol 2006 Mar 3. [Epub ahead of print]
39. Ruof J, Bruhlmann P, Michel BA, Stucki G. Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology Oxford 1999;38:535-42.
40. Danieli E, Airo P, Bettoni L, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005;24:48-54.
41. Hansdottir I, Malcarne V, Furst D, Weisman M, Clements P. Relationships of positive and negative affect to coping and functional outcomes in systemic sclerosis. Cog Ther Res 2004;28:593-610.
42. Nietert PJ, Mitchell HC, Bolster MB, Curran MY, Tilley BC, Silver RM. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol 2005;32:51-7.
43. Prado GF, Allen RP, Trevisani VM, Toscano VG, Earley CJ. Sleep disruption in systemic sclerosis (scleroderma) patients: clinical and polysomnographic findings. Sleep Med 2002;3:341-5.
44. Moser DK. Psychosocial factors and their association with clinical outcomes in patients with heart failure: why clinicians do not seem to care. Eur J Cardiovasc Nurs 2002;1:183-8.
45. Joynt KE, Whellan DJ, O'Connor CM. Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail 2004;10:258-71.
46. Gelber AC, Wigley FM. Disease severity as a predictor of outcome in scleroderma. Lancet 2002;359:277-9.
47. Steen VD. Treatment of systemic sclerosis. Am J Clin Dermatol 2001;2:315-25.
48. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001;44:1359-62.
49. Callahan LF, Smith WJ, Pincus T. Self-report questionnaires in five rheumatic diseases: comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1989;2:122-31.
50. Reveille J, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001;30:332-46.
51. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992;35:216-8.
52. Georges C, Chassany O, Mouthon L, et al. [Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis]. Rev Med Interne 2004;25:16-21.
53. Denton CP, Black CM. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18:271-90.